[Non-muscle-invasive high-grade bladder cancer]

Urologe A. 2015 Apr;54(4):491-8. doi: 10.1007/s00120-015-3774-7.
[Article in German]

Abstract

Background: Non-muscle-invasive bladder cancer with a low-grade differentiation represents a special challenge.

Method: Although urine cytology is still the most reliable and effective urine-based marker and there are no substantial novel aspects in this field, photodynamic diagnostics have the most important value in transurethral resection of the bladder (TURB) of high-grade T1 tumors and new techniques, such as hybrid knife TURB are coming up. The histopathological assessment of T1 tumors can be supplemented by a description of the exact penetration depth, so-called substaging and the invasion pattern.

Results: Intravesicle therapy with Bacillus Calmette-Guèrin (BCG) represents the gold standard and a pillar of bladder-preserving therapy and should be planned as maintenance therapy for at least 1 year. With the right risk constellation cystectomy is a safe and proven concept for high-grade bladder cancer, even without proof of muscle invasion.

Publication types

  • English Abstract

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • BCG Vaccine / therapeutic use*
  • Carcinoma, Transitional Cell / pathology*
  • Carcinoma, Transitional Cell / therapy*
  • Cystectomy / methods
  • Cystoscopy / methods*
  • Humans
  • Muscle Neoplasms / pathology
  • Neoplasm Grading
  • Neoplasm Invasiveness
  • Urinary Bladder Neoplasms / pathology*
  • Urinary Bladder Neoplasms / therapy*

Substances

  • Adjuvants, Immunologic
  • BCG Vaccine